Clinical Trial Update: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating triple immune checkpoint inhibition for advanced or metastatic Merkel cell carcinoma is listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Snippet

Sponsor: University of Washington | Conditions: Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING